EPO and neoplasm: Somatostatin and Erythropoietin (EPO) also have some neuroprotective effects (Hernández et al., 2013; Busch et al., 2014), but a randomized, placebo-controlled study failed to show that the neuroprotective drug Somatostatin was effective in preventing or halting microvascular disease, and there may also be some risk that EPO may promote thrombosis and tumor growth (Barbera and Thomas, 2010; Lippi et al., 2010; Simó et al., 2019).